Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G
· After 12 weeks, 50% of patients treated with pegcetacoplan showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline. · Pegcetacoplan patients showed improvements across key clinical measures, including kidney function and proteinuria. · No approved treatment for IC-MPGN and C3G, rare diseases that often lead to kidney failure. Sobi® and Apellis Pharmaceuticals, Inc. today announced that positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune